Active ingredientAcipimoxCat. No. P-A029-001CAS 51037-30-0Family · Pharmaceutical analytical standards
Acipimox
A derivative of nicotinic acid (niacin, vitamin B3) that originated in Italy and was introduced in Europe in 1985 for hyperlipidaemia: it lowers triglycerides and raises HDL cholesterol. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It curbs the release of fatty acids from fat tissue by acting on the same receptor as niacin; in the body it is not metabolised and leaves intact through the kidneys.
Go to the active ingredient →Active ingredientAcipimoxCat. No. P-A029-001CAS 51037-30-0
Isotopically labelledAcipimox-d4Cat. No. P-A029-002CAS 1246816-28-3
Impurity2-Carboxy-5-methylpyrazine 1,4-dioxideCat. No. P-A029-003CAS 2734844-49-4
Impurity2-Methylpyrazine 1,4-dioxideCat. No. P-A029-004CAS 32046-26-7
Impurity5-Methyl-pyrazinecarboxylic acid 1-oxideCat. No. P-A029-005CAS 98502-96-6
ImpurityAcipimox Impurity 1Cat. No. P-A029-006CAS 51037-31-1
ImpurityAcipimox Impurity 2Cat. No. P-A029-007
ImpurityAcipimox Impurity 3Cat. No. P-A029-008
ImpurityPyrazinecarboxylic acid, 4-oxideCat. No. P-A029-009CAS 874-54-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.